Please login to the form below

Not currently logged in
Email:
Password:

CureVac appoints chief financial officer

Pierre Kemula joins the mRNA company’s management board

CureVac Pierre KemulaTübingen, Germany-based mRNA firm CureVac has appointed Pierre Kemula as its new chief financial officer.

Kemula will have responsibility for managing CureVac's financial and capital markets activities and joins the company's management board.

Previously, Kemula served as chief financial officer of Pixium Vision, a medical technology company specialising in the development of technologies for patients with outer retinal degeneration.

He also brings experience from Ipsen, where he was vice president of corporate finance, treasury and financial markets, and from consulting firms Roland Berger, Kea & Partners, Gemini Consulting and KPMG.

Ingmar Hoerr, co-founder and chief executive officer of CureVac, said: "Adding an executive with Pierre's financial and transactional expertise, as well as his global markets experience, is a key accomplishment for CureVac as the company prepares for multiple near-term corporate and clinical milestones that have the potential to significantly contribute to its leadership position in the field of mRNA."

14th October 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics